1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974.
2. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
5. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 2008;118:9-16.
6. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-part I. Cardiol Rev 2008;16:163-171.
7. Provenzale JM. Imaging of angiogenesis: clinical techniques and novel imaging methods. Am J Roentgenol 2007;188:11-23.
8. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713-725.
9. Riggs TL. Research and development costs for drugs. Lancet 2004;363:184.
10. Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 2006;5:2624-2633.
11. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
13. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:991-1006.
14. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KCP. Detection of tumor angiogenesis in vivo by αvβ3 targeted magnetic resonance imaging. Nat Med 1998;4:623-626.
15. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994;264:569-571.
16. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöcklin G, Schwaiger M. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999;40:1061-1071.
17. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-336.
18. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glyco-peptide and positron emission tomography. Cancer Res 2001;61:1781-1785.
19. Pichler BJ, Kneilling M, Haubner R, Braumüller H, Schwaiger M, Röcken M, Weber WA. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J Nucl Med 2005;46:184-189.
20. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]galactoRGD. PLoS Med 2005;2:e70.
21. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M. Biodistribution and pharmacokinetics of the αvβ3 selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005;46:1333-1341.
22. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M. [18F]galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6610-6616.
23. Mulder WJ, van der Schaft DW, Hautvast PA, Strijkers GJ, Koning GA, Storm G, Mayo KH, Griffioen AW, Nicolay K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J 2007;21:378-383.
24. Zhang C, Jugold M, Woenne EC, Lammers T, Mor-genstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall super-paramagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007;67:1555-1562.
25. Lee BC, Sung HJ, Kim JS, Jung KH, Choe YS, Lee KH, Chi DY. Synthesis of Tc-99m labeled glucosamino-Asp-cyclic (Arg-Gly-Asp-d-Phe-Lys) as a potential angiogenesis imaging agent. Bioorg Med Chem 2007;15:7755-7764.
26. Jung KH, Lee KH, Paik JY, Ko BH, Bae JS, Lee BC, Sung HJ, Kim DH, Choe YS, Chi DY. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med 2006;47:2000-2007.
27. Lee KH, Jung KH, Song SH, Kim DH, Lee BC, Sung HJ, Han YM, Choe YS, Chi DY, Kim BT. Radiolabeled RGD uptake and αv integrin expression is enhanced in ischemic murine hindlimbs. J Nucl Med 2005;46:472-478.
28. Hua J, Dobrucki LW, Daseghi MM, Zhang J, Bourke BN, Cavaliere P, Song J, Chow C, Jahanshad N, van Royden N, Buschmann I, Madri JA, Mendisabal M, Sinusas AJ. Noninvasive imaging of angiogenesis woth a 99mTc labeled peptide targeted at αvβ3 integrin after murine hindlimb ischemia. Circulation 2005;111:3255-3260.
29. Meoli D, Sadeghi M, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, Su H, Edwards DS, Liu S, Harris TD, Madri JA, Zaret BL, Sinusas AJ. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004;113:1684-1691.
30. Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Eur Heart J 2008;29:2201.
31. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Hamilton G, Kurtaran A, Pirich C, Angelberger P, Dudczak R. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003;14:1274-1277.
32. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FG, Backer JM. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 2007;13:504-509.
33. Lu E, Wagner WR, Schellenberger U, Abraham JA, Klibanov AL, Woulfe SR, Csikari MM, Fischer D, Schreiner GF, Brandenburger GH, Villanueva FS. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 2003;108:97-103.
34. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Havlik E, Schima W, Traub-Weidinger T, Graf S, Beheshti M, Schmid M, Angelberger P, Dudczak R. Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. Q J Nucl Med Mol Imaging 2004;48:198-206.